Valacyclovir for HSV Suppression
For suppressive therapy to prevent recurrent HSV, use valacyclovir 500 mg twice daily in HIV-infected patients, or 1 gram once daily (alternatively 500 mg once daily for ≤9 recurrences/year) in immunocompetent patients. 1
Dosing by Patient Population
Immunocompetent Patients
- Standard dose: 1 gram once daily 1
- Alternative for infrequent recurrences (≤9 episodes/year): 500 mg once daily 1
- Important caveat: The 500 mg once daily dose is less effective in patients with very frequent recurrences (≥10 episodes/year) 2
HIV-Infected Patients
- Required dose: 500 mg twice daily 3, 1
- This twice-daily regimen is mandatory for HIV-infected individuals—once-daily dosing is insufficient 3
- Suppressive therapy in HIV patients also decreases HIV viral load in plasma and genital secretions 3
Clinical Efficacy
Daily suppressive therapy reduces genital herpes recurrences by ≥75% in patients with frequent recurrences (≥6 per year) 2. The evidence demonstrates:
- 65-69% of patients remain recurrence-free during continuous suppressive therapy 4, 5
- Valacyclovir 500 mg twice daily shows an 80% reduction in recurrence risk compared to placebo (hazard ratio 0.20) 6, 4
- Once-daily regimens show dose-response relationships, with higher doses more effective for frequent recurrences 7
Duration and Monitoring
- Safety documented for acyclovir up to 6 years; valacyclovir data available for 1 year as of older guidelines 2
- Reassess annually: After 1 year of continuous therapy, discuss discontinuation to evaluate recurrence patterns, as frequency naturally decreases over time in many patients 2
- No laboratory monitoring needed unless substantial renal impairment exists 3
Critical Safety Considerations
Renal Dosing Adjustments
For creatinine clearance 30-49 mL/min:
- Suppressive therapy in immunocompetent patients: 500 mg every 24 hours
- HIV-infected patients: 500 mg every 24 hours 1
For creatinine clearance 10-29 mL/min:
- All suppressive regimens: 500 mg every 24 hours 1
High-Dose Warning
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome has been reported in HIV-infected patients receiving high-dose valacyclovir (8 grams/day), but not at standard suppressive doses 3. This is a critical distinction—standard suppressive doses (500 mg-1 gram daily) are safe.
Transmission Reduction
For reduction of transmission to uninfected partners in immunocompetent patients with ≤9 recurrences/year: 500 mg once daily 1. However, suppressive therapy reduces but does not eliminate asymptomatic viral shedding 2.
Common Pitfalls to Avoid
- Underdosing HIV patients: Do not use once-daily dosing in HIV-infected individuals—they require 500 mg twice daily 3
- Using 500 mg once daily for frequent recurrences: This dose is inadequate for patients with ≥10 recurrences/year 2
- Forgetting renal adjustment: Always check renal function and adjust accordingly 1
- Confusing episodic with suppressive dosing: Episodic treatment (500 mg twice daily for 3 days) is different from suppressive therapy (daily dosing) 1